| Cash and cash equivalents |
84.28M |
| Short-term investments |
603.57M |
| Contracts receivable |
8.54M |
| Inventories |
9.32M |
| Other current assets |
15.24M |
| Total current assets |
730.33M |
| Property, plant and equipment, net |
90.97M |
| Licenses, net |
| Patents, net |
| Deposits and other assets |
| Total assets |
843.59M |
| Accounts payable |
15.68M |
| Accrued compensation |
11.01M |
| Accrued liabilities |
23.62M |
| Current portion of long-term obligations |
49K |
| Current portion of deferred contract revenue |
56.54M |
| Total current liabilities |
106.89M |
| Long-term deferred contract revenue |
101.83M |
| 2 5/8% convertible subordinated notes |
| Long-term obligations, less current portion |
| Long-term financing liability for leased facility |
| Investment in Regulus Therapeutics Inc. |
| Total liabilities |
703.95M |
| Common stock, $0.001 par value; 200,000,000 shares authorized, 99,618,525 and 99,393,780 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively |
121K |
| Additional paid-in capital |
1.37B |
| Accumulated other comprehensive income |
-26.5M |
| Accumulated deficit |
-1.21B |
| Total stockholders' equity |
| Total liabilities and stockholders' equity |
843.59M |
